Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


Report this comment to a moderator

Please fill in the form below if you think a comment is unsuitable. Please indicate which comment is of concern and why. Your comments will be sent to our moderator for review.

Report comment to moderator

MandatoryRequired fields.


Everything you need to know about the COVID-19 therapy trials


Thanks for this fantastic resource. However I think you've misinterpreted the findings of the REMAP-CAP hydrocortisone arm - "93% more likely to have a better outcome" suggests a very impressive relative risk reduction; in actual fact the trial showed no significant difference in outcome, having been terminated early. They somewhat confusingly reported a "93% probability of superiority" (i.e. p value 0.07) which did not meet their pre-specified alpha. I think they should have represented this as simply "did not demonstrate superiority, having been terminated early".

Posted date

7 OCT 2020

Posted time



Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.